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Human carboxylesterase 2 (hCES2) is a glycoprotein involved in the metabolism of drugs and several
environmental xenobiotics, whose crystallization has been proved to be a challenging task. This lim-
itation could partly be due to glycosylation heterogeneity and has delayed the disclosure of the 3D
structure of hCES2 which would be of upmost relevance for the development of new substrates and
inhibitors. The present work evaluated the involvement of glycans in hCES2 activity and thermo stability
in an attempt to ﬁnd alternative active forms of the enzyme that might be adequate for structure elu-
cidation.
Partial or non-glycosylated forms of a secreted form of hCES2 have been obtained by three ap-
proaches: (i) enzymatic deglycosylation with peptide N-glycosidase F; (ii) incubation with the inhibitor
tunicamycin; ii) site directed mutagenesis of each or both N-glycosylation sites.
Deglycosylated protein did not show a detectable decrease in enzyme activity. On the other hand,
tunicamycin led to decreased levels of secreted hCES2 but the enzyme was still active. In agreement,
mutation of each and both N-glycosylation sites led to decreased levels of secreted active hCES2. How-
ever, the thermostability of the glycosylation mutants was decreased.
The results indicated that glycans are involved, to some extent in protein folding in vivo, however,
removal of glycans does not abrogate the activity of secreted hCES2.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Carboxylesterases (CES) are a subset of esterases that belong to
the α/β hydrolase family [35]. These enzymes catalyze the hy-
drolysis of esters, thioesters and amides, freeing the respective
carboxylic acid and alcohol [14]. Carboxylesterases are responsible
for detoxifying exogenous substrates, like pesticides and other
environmental toxicants and are also involved in metabolizing
drugs and/or activating pro-drugs [24]. In fact, after oxidative
enzymes such as cytochrome (CYP) P450 enzymes and UDP-glu-
curonosyltransferases (UGTs), esterases are the third major class of
enzymes involved in the metabolic clearance of currentlyB.V. This is an open access article u
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l.pt (J. Costa),administered therapeutic drugs [13,34]. Speciﬁc inhibitors for CESs
have been reported, such as bis-p-nitrophenyl phosphate (BNPP)
and benzyl [29,39]. Due to their potential pharmacological appli-
cation, the search for individual CESs speciﬁc inhibitors is, in fact,
an active research ﬁeld [20,28,32,40,41,5,7,8].
hCES have different tissue distribution, localization within the
cell and substrate preferences [14] with some overlapping. More-
over they have different genetic variants resulting from alternative
splicing, single nucleotide polymorphisms (SNPs) and multiple
copy variants that have been shown to inﬂuence drug metabolism
and clinical outcomes [16,23]. Human CES enzymes encompass a
signal peptide of approximately 17 to 22 aminoacid residues re-
sponsible for their targeting to the endoplasmic reticulum (ER)
where they are retained due to a carboxy-terminal ER retention
signal – the H-X-E-L (Histidine – X – Glutamic Acid – Leucine)
consensus sequence that interacts with the KDEL (Lysine – As-
partic Acid – Glutamic Acid – Leucine) receptor present in the
luminal side of the ER [26]. This is in accordance with the absence
of CES from human plasma, contrary to what happens in most
rodents [1,25].
Three main human carboxylesterases have been most studiednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Enzymatic deglycosylation of hCES2-10xHis with PNGase F. (A) Western Blot
demonstrating size reduction upon denaturing and native deglycosylation of su-
pernatants (25 mg of total protein per well). (B) Denaturing and native deglycosy-
lation of puriﬁed hCES2-10xHis and staining with ProQ Emerald 300 (5 mg of total
protein per well). Lanes: 1 – hCES2-10xHis under denaturing conditions, (PNGase F
-); 2 – hCES2-10xHis under denaturing conditions (PNGase F þ); 3 – hCES2-10xHis
under native conditions (PNGase F -); 4 –hCES2-10xHis under native conditions
deglycosylated (PNGase F þ).
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Organization database: hCES1, hCES2 and hCES3 [23]. Human CES1
has traditionally been the most studied hCES, however, increased
attention has been devoted to hCES2 due to its role in the acti-
vation of prodrugs, its potential application in prodrug-activating
gene therapies [30,38] and also its involvement in pre-systemic
metabolism of orally administered drugs. Human CES2 is found in
different tissues like the liver and kidney being in fact the major
intestinal carboxylesterase [6] and it has been reported to be
downregulated in some cancers [15] while overexpressed in others
[35].
Contrary to hCES1, which has a substrate preference for esters
with small alcohol group, hCES2 hydrolyzes preferentially sub-
strates with a large alcohol group and a small acyl group as is the
case of irinotecan [11], some angiotensin receptor blockers as well
as aspirin, having a consequent effect in their bioavailability
[22,27].
While hCES1 is so far the only human CES form that has a fully
known structure [2], the tertiary structure of hCES2 has been
elusive to many scientists for more than a decade. hCES2 has two
potential N-glycosylation sites, at Asn103 and Asn267 [26]. The
puriﬁed native human enzyme has been shown to be sensitive to
endoglycosidase H (Endo H), which hydrolyzes Asn-linked high
mannose oligosaccharides [21]. On the other hand, recombinant
hCES2 from HEK-293T cells has been efﬁciently deglycosylated
with PNGase F but not Endo H, indicating that it was further
modiﬁed at the Golgi apparatus [12]. However, taking into account
that the efﬁciency of glycosylation can be affected by conforma-
tional limitations and by the acidicity of “X” residue (any amino
acid except proline) in the Asn-X-Ser/Thr sequons where N-gly-
cosylation may occur [31], the number of occupied N-glycosylation
sites has not in fact been conﬁrmed. Accordingly, for rat carbox-
ylesterases, the intracellular form is sensitive to Endo H whereas
the secreted form is only sensitive to PNGase F [17].
The effect of glycosylation on hCES2 activity is not known and
the data available on other carboxylesterases is not always con-
sensual. For example, Hydrolase C, a rat carboxylesterase, has been
shown to be inactive when expressed in E. coli, a prokaryotic or-
ganism, but active when expressed in the baculovirus/insect cell
(Spodoptera frugiperda 21 – Sf21) system [36,37]. In addition, the
expression of a recombinant rabbit liver carboxylesterase in E. coli
yielded an inactive protein which was attributed to the lack of
N-glycosylation, whereas an active protein was obtained from
yeast cell expression system (Pichia pastoris), capable of N-glyco-
sylation [18]. However, despite previous claims that, for full ac-
tivity of recombinant hCES1, expressed in the baculovirus-insect
cell system, proper glycosylation (especially N-linked glycosyla-
tion) was necessary [10], difﬁculties in obtaining an active form of
hCES-1 from E. coli have recently been attributed to issues related
to the protein being expressed in inclusion bodies and with low
purity [3]. The authors have refolded the enzyme via buffer ex-
change and obtained an active form, thus questioning previous
claims on the need of proper glycosylation for production of a
recombinant active form. Additionally, [17] found that native de-
glycosylation of rat carboxylesterases (hydrolases A and B), pur-
iﬁed from rat liver microsomes, has no effect on enzyme activity.
The authors hypothesized that these data may point towards a
higher relevance of glycosylation for protein stability and solubi-
lization and not as much for enzymatic activity of mature proteins.
The 3D structure of hCES2 has not been deciphered yet, mostly
because its crystallization has been a challenging task. Glycopro-
teins are many times difﬁcult to crystallize due to the hetero-
geneity of N-glycan structures and conformations at the surface of
proteins and therefore we considered the production of non-gly-
cosylated forms of hCES2in order to obtain alternatives for crys-
tallization and diffraction studies. However, since these new formswould only be useful for structural studies if they remained active,
the main goal of the present work was to evaluate the impact of
glycosylation in hCES2 activity. For that purpose, several strategies
[4] were tested to prevent or remove glycosylation, and test the
impact on enzyme activity and stability, namely: recombinant
hCES2, secreted from HEK-293T cells [12], was enzymatically de-
glycosylated (1); N-glycosylation was inhibited during production
(2) or the N-glycosylation sites were mutated (3).2. Results and discussion
2.1. Effect of enzymatic degycosylation on enzyme activity
In order to test if N-glycosylation was relevant for enzyme ac-
tivity, the supernatant of HEK293T cells transfected with pCI-neo
hCES2-10xHis [12] was subjected to enzymatic deglycosylation
with PNGase F under denaturing and native conditions. In both
conditions, a downward shift in molecular weight of under 10 kDa
was observed by Western Blot (Fig. 1A). In native conditions the
results indicated incomplete digestion that could not be improved
with a longer incubation period, or by increasing the amount of
enzyme. This can be explained by limited accessibility of the en-
zyme to one of the N-glycosylation sites. Deglycosylation of pur-
iﬁed hCES2-10xHis [12] showed a decreased level of detection
using the glycoprotein detection method ProQ Emerald 300 with
the deglycosylated bands only being faintly detected probably due
to non-speciﬁc binding or to O-glycosylation (Fig. 1B).
Enzyme activity was assessed on supernatants subjected to
native deglycosylation, (PNGaseþ) and compared with the control
(PNGase-) as described in the Materials and Methods section. No
evidence of decay in total hydrolytic activity was observed as
speciﬁc activities were respectively 93.973.7 pM s1 mg1
(PNGaseþ) and 88.976.4 pM s1 mg1 for PNGase- and PNGaseþ
samples, respectively. It can therefore be concluded that the pre-
sence of N-glycans in the mature form of the protein – fully pro-
cessed through the cell machinery – is not essential for protein
activity.
These results are in accordance with the observations of [17]
which refered that rat liver hydrolase A and B remained active
after enzymatic deglycosylation.
Fig. 2. Supernatant from cell cultures treated with tunicamycin (TMþ) or DMSO
(TM) were harvested at 24 and 48 h. (A) Western Blot of the supernatants, 25 mg
of total protein per well; (B) Relative activity of hCES2-10xHis in the presence or
absence of tunicamycin. Results are the average of three determinations, error bars
represent the standard deviation (n¼3).
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As previously referred, different authors have presented con-
tradictory results relative to the effect of glycosylation in carbox-
ylesterase activity [19,3,4,9], and therefore we hypothesized that,
although the removal of glycans post synthesis might not affect
activity, the presence of glycans during protein synthesis could be
necessary for the correct folding of the enzyme. In order to test
this hypothesis, hCES2-10xHis expression was achieved in the
presence of tunicamycin, an inhibitor of the formation of the
N-glycan precursor [10,31].
As expected, this process resulted in the production of a lighter
form of the protein, as conﬁrmed by Western Blot, which is con-
sistent with the absence of glycosylated residues (Fig. 2A). An
accentuated decrease in hCES2-10xHis expression is also apparent
from relative band intensity (2:100 after 24 h and 8:100 after 48 h)
in the presence (TMþ) and absence (TM)of tunicamycin, despite
similar cell viability (the use of a housekeeping control, for nor-
malization purposes, was not possible since analyses were per-
formed in supernatants). Such decay is not likely to be due to
reduced antibody afﬁnity towards the non glycosylated form since
this has not been observed when deglycosylation was achieved
through enzyme hydrolysis (Fig. 1A).
The lower levels of protein observed in the presence of tuni-
camycin might be due to a folding limitation for the non-Fig. 3. Schematic representation of pCI-neo hCES2-10xHis mutant plasmids lacking one
The coding sequence of each plasmid contained a signal peptide (white rectangle) and th
rectangles.glycosylated protein with subsequent degradation due to the
quality control mechanism of glycoproteins involving calnexin in
the endoplasmic reticulum [33] since we observed that tunica-
mycin did not affect cell viability or total protein concentration.
The lower levels detected in the supernatant may also be due to
intracellular accumulation of the non-glycosylated protein. Further
experiments are required to clarify this issue.
Accordingly, supernatants from TMþ cultures had signiﬁcantly
lower hydrolytic activity towards 4-MUBA than those of the con-
trol cultures. However, taking into account that fainter bands were
observed for the TMþ cultures, the observed reduction in 4-MUBA
hydrolysis is more likely to be due to the lower amount of hCES2-
10His expressed in the presence of tunicamycin rather than from
an effective decrease in enzyme catalytic ability. Moreover, the
reduction in activity is not as accentuated as the decay in band
intensity. Therefore it is possible to claim that hCES2 does not fully
lose its catalytic activity even when glycosylation is prevented at
early stages of protein production (Fig. 2B). These results are in
accordance with results from other authors that demonstrated to
be possible to produce an active recombinant non-glycosylated
hCES1 [3].
2.3. Mutation of N-glycosylation sites of hCES2
In order to fully conﬁrm the number of glycosylation sites, as
well as the individual relevance of each site for activity, glycosy-
lation was prevented through a different approach that consisted
in using site directed mutagenesis to replace the asparagine re-
sidues in the Asn-X-Ser/Thr sequons, by glutamine thus precluding
binding of the sugar moieties to those putative sites.
For that purpose, each or the two potential N-glycosylation
sites were mutated resulting in three mutated forms of the protein
which lacked either the ﬁrst (p.Asn175Gln, Glyco1), the second (p.
Asn340Gln, Glyco2) or both (p.Asn175Gln/Asn340Gln, Glyco1þ2)
glycosylation sites (Fig. 3).
Through Western Blot it was possible to conﬁrm a decrease in
the molecular weight of the mutant forms present in the cell
culture supernatants in comparison with the positive control (fully
glycosylated hCES2-10xHis); as expected the difference in weight
was larger in the case of the double mutant (Fig. 4A) and con-
sistent with the decrease observed upon culturing in the presence
of tunicamycin. These results unequivocally conﬁrmed that the
two previously described putative glycosylation sites of hCES2 [26]
are in fact glycosylated.
Relative expression of hCES2-10xHis also decreased in the case
of the mutants according to relative band intensities (Fig. 4A):
100%, 73%, 66% and 22% respectively for PC, Glyco2, Glyco1 and
Glyco1þ2. These results are in agreement with those obtained for
protein expression in presence of tunicamycin. In this case it could
also be due to folding impairment in the absence of the glycans
that lead to protein degradation in context of the quality control
mechanism associated with calnexin in the endoplasmic re-
ticulum, or it could be due to intracellular accumulation of the
protein.
The supernatants containing the mutated forms of hCES2-
10xHis were tested for enzymatic activity (normalized to total(p.Asn175Gln, p.Asn340Gln) or two (p.Asn175Gln/Asn340Gln) glycosylation sites.
e 10xHis tag (light gray rectangle). Glycosylation sites are represented by the black
Fig. 4. Glycosylation site mutants and positive control (fully glycosylated hCES2-
10xHis) present in cell culture supernatants were analyzed. (A) Western blot ana-
lysis, 25 mg of total protein per well. (B) Relative activity of the mutants comparing
to the positive control. Results are the average of three determinations; error bars
represent the standard deviation of the triplicates. PC – positive control, hCES2-
10xHis; Glyco 1 – hCES2-10xHis lacking the ﬁrst glycosylation site; Glyco 2 –
hCES2-10xHis lacking the second glycosylation site; Glyco 1þ2 – hCES2-10xHis
lacking both glycosylation sites; NC – negative control, supernatant of non trans-
fected cells.
Fig. 5. Relative activity of glycosylation site mutants and of fully glycosylated
hCES2-10xHis (PC) after being subjected to a temperature gradient (normalized to
the activity observed at 37 °C in each case). Results are average of three determi-
nations; error bars represent the standard deviation of the triplicates. PC – positive
control, hCES2-10xHis; Glyco 1 – hCES2-10xHis lacking the ﬁrst glycosylation site;
Glyco 2 – hCES2-10xHis lacking the second glycosylation site; Glyco 1þ2 – hCES2-
10xHis lacking both glycosylation sites. * Indicates a statistically signiﬁcant differ-
ence (Po0.05) in activity observed in the mutants in relation to the activity of the
PC at the same temperature.
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highest speciﬁc activity toward 4-MUBA, while Glyco 1 and Glyco
2 retained approximately 60% of the control activity and Glyco
1þ2 dropped to 25% of activity (Fig. 4B).
These results thus indicate that the loss in the relative activity
of the supernatants is more likely due to lower expression of the
mutants than to loss of catalytic ability of the protein upon loss of
glycosylation. This conclusion contradicts the observation of other
authors who have not been able to obtain active carboxylesterases
(rat and rabbit) upon expression in prokaryotic systems [18,36,37])
but are in agreement with recent studies demonstrating that it is
possible to obtain active hCES-1 from E. coli upon post puriﬁcation
refolding, despite the lack of glycosylation machinery in prokar-
yotes [3].
2.4. Thermal stability of N-glycosylation mutants
As previously referred, the tridimensional structure of hCES2
has not yet been determined. According to our experience this task
has not been achieved due to difﬁculties in obtaining crystals of
adequate size and stability for allowing diffraction studies (results
not shown) which may be related to enzyme stability. Considering
that conformation of the protein, its stability and crystallizing
aptitude may be inﬂuenced by the glycosyslation proﬁle, thermal
stability of the glycosylated protein and of the mutants was eval-
uated by quantifying the activity of the supernatants subjected to a
temperature gradient (Fig. 5).
Stability of the mutants subjected to higher temperatures, in
comparison with the respective control (activity observed at37 °C), was not signiﬁcantly affected at 41.2 °C. However, higher
temperatures promoted a relative decrease in activity that was
more accentuated in the case of the double mutant.3. Conclusions
In conclusion, N-glycosylation of hCES2 is relevant for ther-
mostability of the enzyme and also for its in vivo folding or se-
cretion, but is not crucial for enzyme activity. Since the partial or
non-glycosylated mutants are still secreted to some extent in an
active form they constitute promising candidates for future
structural studies.4. Materials and methods
4.1. Cell culture and transfection
Suspension adapted Human embryonic kidney cells (HEK-293T;
ATCC CRL-11268) were cultured using Frestyle 293 medium (Gib-
co, Life Technologies; USA). The cells were sub-cultured twice a
week using an inoculum of 0.3106 cells/mL and incubated in a
humidiﬁed atmosphere of 8% CO2 at 37 °C, with orbital agitation at
130 rpm.
To determine cell viability and concentration the Trypan Blue
exclusion method was used; the cellular suspension samples were
diluted in 0.1% Trypan Blue (Gibco, Life Technologies; USA) solu-
tion prepared in PBS (Gibco, Life Technologies; USA) and the cells
were counted twice on a Fuchs-Rosenthal haemacytometer (Mar-
ienfeld; Lauda-Konigshofen, Germany).
The pCIneo hCES2-10xHis mammalian expression vector, was
generated as previously described [12]. Brieﬂy, human re-
combinant CES2 gene synthetically synthesized with a C-terminal
10xHis tag (GeneArt; Regensburg, Germany) was cloned in pCI-neo
plasmid (Promega; Madison, USA.) using SalI and NotI restriction
endonucleases (New England Biolabs; Ipswich, USA). For the for-
mation of a full transcript containing the C-terminal histidine tag,
Table 1
Primers designed for the site directed mutagenesis reactions. Tm: melting tem-
perature; GC – Guanine Cytosine Content. GS1 pair of primers was used to mutate
the ﬁrst, while the GS2 was used to mutate the second glycosylation site.
Name Sequence (5′–3′)
GS1 Fw TAGCCAGTTCCAGATGACCTTCCCTTCCGACTCCATGTCT
GS1 Rv GGAAGGTCATCTGGAACTGGCTAAGAAACTCTGACTCCACT
GS2 Fw GGTGGTGGCCCAGCTGTCTGCCTGTGACCAAGTTG
GS2 Rv ACACCGAGACAGCTGGGCCACCACCGTGGAGATGACA
M. Alves et al. / Biochemistry and Biophysics Reports 5 (2016) 105–110 109the stop codon of CES2 gene was deleted.
Transient transfection of HEK-293T was performed using
polyethylenimine (PEI, Polysciences; Eppelheim, Germany). A
transfection solution of 1 mL containing fresh medium and plas-
mid DNA:PEI at a ratio of 1:3, in which DNA concentration was
5 mg/mL, was vortexed, incubated for 10 minutes (min) at room
temperature and added dropwise to the cell culture. Cell growth
and viability was followed throughout a time period of 72 h (hours
). The cell culture was then centrifuged for 10 min at 300 g, and
the supernatant was harvested.
Quantiﬁcation of total protein in cell culture supernatant was
performed using the Bradford Assay in triplicate according to the
manufacturer's instructions in a 96 well plate with Coomassie
Brilliant Blue G-250 (Bio-Rad, USA).
4.2. SDS-PAGE and Western Blot
Ice cold ethanol was added to the samples (100 mg of total
protein) in a ratio of 1:4 and incubated for 2 h at 20 °C, for
protein precipitation. Precipitated protein was resuspended in
Sample Buffer and Reducing Agent (20 mL) and heated to 70 ºC for
20 min. 10 mL of each sample (50 mg of total protein) were loaded
onto the wells of a NuPAGE BisTris 4–12% (w/v) acrylamide gel,
using the X-Cell Surelock mini cell system and MES (2-(N-mor-
pholino)ethanesulfonic acid) Running Buffer. Electrophoresis ran
for 40 min at 200 V. All of the reagents and materials used were
from Life Technologies, USA.
The gel was transferred onto a PVDF (polyvinylidene diﬂuoride)
or nitrocellulose membrane, using the Transblot Turbo Semi Dry
Transfer System (Bio-Rad, USA) for 25 min at 25 V. The membrane
was blocked in 5% (w/v) milk (skim milk for microbiology, Merck,
USA) in 0.05% (v/v) Tween 20 (Merck, USA)/Tris Buffered Saline
(TBS, Sigma-Aldrich, USA) overnight. The membrane was in-
cubated for 1 h with the goat anti-hCES2 primary antibody (R&D
Systems, USA) diluted 1:200, followed by 1 h in secondary anti-
body, HRP-mouse anti-goat, diluted 1:5000. The antibodies were
diluted in 1% (w/v) bovine serum albumin (BSA, Sigma-Aldrich,
USA) in 0.05% (v/v) Tween 20/TBS solution. Washings were done
with Tween/TBS. Detection was by chemilluminescence using ECL
Amersham (GE Life Sciences, UK), and images were collected using
ChemiDoc (Bio-Rad, USA).
4.3. Enzymatic deglycosylation through digestion with PNGase F
HEK-293T transfected cell supernatants containing hCES2
10xHis were concentrated using Amicon Ultra-15, PLTK Ultracel-PL
Membrane, 30 kDa (Merck Milipore, USA) and quantiﬁed for total
protein concentration.
Glycoproteins from concentrated supernatants were deglyco-
sylated using peptide N-glycosidase F (PNGase F; ProZyme, USA).
The reactions were performed under two different sets of condi-
tions: the native reaction (1) consisted in adding 50 mU of enzyme
(PNGaseF) to 100 mg of sample in the reaction buffer, while the
denaturing reaction (2) required heating at 100 °C for protein
denaturing, prior to adding 10 mU of PNGaseF. Both reactions were
incubated overnight at 37 °C. Deglycosylation was monitored by
SDS-PAGE and Western Blot.
Puriﬁed hCES2-10xHis [12]) was also subjected to deglycosy-
lation with PNGase F and deglycosylation was monitored by SDS-
PAGE, followed by staining ProQ Emerald 300 (Life Technologies,
USA) that stains glycosylated proteins.
4.4. Enzymatic inhibition of N-glycosyslation
In order to produce a non-glycosylated form of hCES2-10xHis,
HEK293T cells transfected with pCI-neo hCES2-10His wereincubated for 4 h at 37 °C, 8% CO2 and 130 rpm orbital agitation,
after which the cell culture was split and centrifuged (200 g,
10 min). The supernatant was then replaced with fresh medium
containing either 2 mg/mL of tunicamycin solubilized in di-
methylsulfoxide (DMSO) or, as control, the same volume of DMSO.
The cell cultures were again incubated for 48 h under the same
conditions, and cell viability was assessed at several time points.
Total protein concentration and esterase activity were determined
as previously described.
4.5. Mutation of N-glycosylations sites
For conﬁrmation of the putative N-glycosylation sites, the as-
paragine residue from the Asn-X-Ser/Thr sequons in pCIneo
hCES2-10xHis mammalian expression vector were substituted by a
glutamine using the GeneArt Mutagenesis Kit (Life Technologies,
USA, ref. A13282) according to the manufacturer's instructions.
These mutations preclude N-glycosylation.
Two pairs of primers were designed, one pair for each glyco-
sylation site, resulting in two single mutants: N175Q and N340Q. A
double mutant plasmid, N175Q/N340Q, was also obtained through
two consecutive mutagenesis reactions, one for each set of primers
(Table 1). Mutations were conﬁrmed by DNA sequencing.
HEK-293T cells were transfected with these plasmids as pre-
viously described. The supernatants were quantiﬁed for total
protein and tested for ester hydrolysis activity.
4.6. Enzyme activity assays
For the evaluation of enzymatic activity of the expressed en-
zymes the hydrolysis of 4-methylumbelliferyl acetate (4-MUBA) to
4-methylumbelliferone (4-MUB) was measured by spectro-
ﬂuorimetry (FL800 Bio-Tek Instruments, Winooski, VT, USA). Every
assay, including controls, was performed in triplicate, and results
are presented as the average7standard deviation. Correction for
non-enzymatic hydrolysis was performed.
The substrate stock solution, 15 mM 4-MUBA (Sigma-Aldrich,
USA), was prepared in DMSO (Sigma-Aldrich, USA). This solution
was diluted to 7.5 mM in a 1:1 mixture of Hank's Balanced Salt
Solution (HBSS, Life Technologies, USA)/DMSO. For determination
of total esterase activity, 5 mM of substrate was added to the
sample diluted in HBSS to a ﬁnal reaction volume of 250 mL. Re-
actions were followed at 37 °C, at λex¼350 and λem¼450 nm for
15 min, in 50 s intervals and enzymatic activity was determined
from the linear portion of the curve. A stock solution of 4-MUB
(Sigma-Aldrich, USA) 15 mM was also prepared in 5 mL DMSO and
then diluted in HBSS, to prepare the calibration curve in the range
0.002–0.075 mM .
For the determination of speciﬁc hCES2 activities, inhibition
assays were performed, in the presence of 0.025 mM loperamide
(Sigma-Aldrich, USA), selective inhibitor of hCES2 [9], while for
determination of speciﬁc CES activities assays were performed in
the presence of 0.5 mM of Bis(4-nitrophenyl) phosphate (BNPP,
Sigma-Aldrich, USA), which is a CES inhibitor [19]. The inhibitors
were added prior to substrate addition. Final DMSO concentration
M. Alves et al. / Biochemistry and Biophysics Reports 5 (2016) 105–110110in the reaction mixture never exceeded 1% (v/v) in order not to
affect hCES catalytic activity [33].
4.7. Thermal stability
Supernatant samples were subjected to a non-linear tempera-
ture gradient using a BioRad IQ Cycler IQ5 (Bio-Rad, USA) for
3 min. After incubation the samples were centrifuged at
13,000 rpm, 4 °C for 15 min. The pellets, which contained dena-
tured protein, were discarded, and the supernatants were tested
for enzymatic activity as described above.Acknowledgment
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